Splicing factor SC35 promotes tau expression through stabilization of its mRNA  by Qian, Wei et al.
FEBS Letters 585 (2011) 875–880journal homepage: www.FEBSLetters .orgSplicing factor SC35 promotes tau expression through stabilization of its mRNA
Wei Qian a,b, Khalid Iqbal b, Inge Grundke-Iqbal b, Cheng-Xin Gong b,⇑, Fei Liu a,b,⇑
a Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong, Jiangsu 226001, PR China
bDepartment of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314, USA
a r t i c l e i n f oArticle history:
Received 31 December 2010
Revised 28 January 2011
Accepted 14 February 2011
Available online 17 February 2011
Edited by Jesus Avila
Keywords:
Tau
Alzheimer’s disease
SC35
mRNA stabilization0014-5793/$36.00  2011 Federation of European Bio
doi:10.1016/j.febslet.2011.02.017
⇑ Corresponding authors. Address: Department of
State Institute for Basic Research in Developmental D
10314, USA (F. Liu). Fax: +1 718 494 1080.
E-mail addresses: chengxin.gong@csi.cuny.edu (C
com (F. Liu).a b s t r a c t
Altered alternative splicing and accumulation of brain microtubule-associated protein tau are found
in several tauopathies and are believed to lead to these neurodegenerative diseases. We found that
in addition to promoting tau exon 10 inclusion, splicing factor SC35 also promoted tau expression in
HEK-293T cells. The activity of SC35 in promotion of tau expression was limited to exon 10 contain-
ing tau isoforms. SC35 did not affect tau transcription, but stabilized tau mRNA by binding to the
SC35-like element of exon 10. These results provide novel insight into the regulation of tau expres-
sion and a molecular mechanism of tauopathies.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The microtubule-associated protein tau interacts with tubulin
to promote the assembly and stabilization of microtubules [1].
Neurodegenerative tauopathies, including Alzheimer’s disease
(AD), are histopathologically characterized by the formation of
neuroﬁbrillary tangles (NFTs), which are composed of abnormally
hyperphosphorylated forms of tau, in the brain [2–4]. It has been
proposed that several different molecular mechanisms are in-
volved in the development of NFTs [5].
Increased tau level has been observed in the brains of individu-
als with AD and Down syndrome [6,7]. High expression of tau in
cultured cells results in cell toxicity and accumulation of the mito-
chondria in the perinuclear region [8]. Suppression of endogenous
soluble tau or expressed human tau reduces the rate and degree of
cognitive decline in transgenic mouse models of AD [9,10]. There-
fore, reducing tau accumulation could be a therapeutic approach
for neurodegenerative tauopathies.
Six isoforms of tau protein expressed in adult human brain are
derived from a single tau gene by alternative splicing of its
pre-mRNA [11,12]. The presence or absence of the second
microtubule-binding repeat, which results from alternative splic-
ing of tau exon 10, divides tau isoforms into two groups, 3R-tauchemical Societies. Published by E
Neurochemistry, New York
isabilities, Staten Island, NY
.-X. Gong), feiliu63@hotmail.(containing three microtubule-binding repeats) and 4R-tau
(containing four such repeats) [12,13]. Normal adult human brain
expresses approximately equal levels of 3R-tau and 4R-tau
[14–16]. Disrupted 3R/4R-tau ratios have been found in several
tauopathies [17–19]. Therefore, equal levels of 3R-tau and 4R-tau
might be critical for maintaining optimal neuronal physiology [18].
The SR (serine/arginine rich) proteins are important in regulat-
ing alternative splicing [20]. They also play additional roles in dif-
ferent aspects of RNA processes, including transcription, RNA
stability, mRNA transport, and mRNA translation [21]. SC35 was
one of the prototypical SR proteins identiﬁed by monoclonal anti-
bodies directed against puriﬁed spliceosomes [22,23]. Recently, it
has been reported that SC35 may be essential for genomic stability
[24] and that SC35 has an active role in transcriptional elongation
[25].
To determine the role of SC35 in RNA processing and expression
of tau, we investigated the effect of SC35 on tau mRNA and protein
expressions in cultured cells. We found that SC35 stabilized tau
mRNA by binding to the exon 10 and promoted tau expression in
a manner dependent on its exon 10.
2. Materials and methods
2.1. Plasmids and antibodies
pEGFP/tau23, pEGFP/tau24, pEGFP/tau37, pEGFP/tau46, pEGFP/
tau39, and pEGFP/tau40 were subcloned from pKR172/taus (a gift
from M. Goedert of Medical Research Council Laboratory of Molec-
ular Biology, Cambridge, United Kingdom) into the BglII and EcoRIlsevier B.V. All rights reserved.
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pCI/tau40 were subcloned from pEGFP/tau39 and pEGFP/tau40
into the XhoI/XbalI sites of PCI-neo vector (Clontech). pCEP4/
SC35-HA was a gift from Dr. Tarn of the Institute of Biomedical
Sciences, Academia Sinica, Taiwan. Polyclonal anti-tau (R134d)
was described previously [26]. The monoclonal anti-HA and anti-
b-actin were bought from Sigma (St. Loius, MO). Peroxidase-
conjugated anti-mouse and anti-rabbit IgG were obtained from
Jackson ImmunoResearch Laboratories (West Grove, PA).
2.2. Cell culture and transfection
HEK-293T cells were maintained in Dulbecco’s Modiﬁed Eagle’s
Medium supplemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA, USA) at 37 C. The cells were transfected by using
FuGENE 6 (Roche Diagnostics, Indianapolis, IN) according to
manufacture’s protocol.
2.3. Expression and puriﬁcation of HA-SC35
pCEP4-SC35 was transfected into HEK-293T Cells using FuGENE
6 for 48 h, and then the cells were lysed in 0.5 ml of IP lysis/wash
buffer (Pierce Crosslink Immunoprecipitation Kit, Thermo Scien-
tiﬁc, Rochford, IL, USA). The cell lysates were mixed with anti-HA
cross-linked to protein G-Sepharose beads and incubated at 4 C
overnight. After extensive washing, SC35 was eluted in three suc-
cessive 100 ll fractions with elusion buffer provided in the kit
and neutralized with 1 M Tris.
2.4. In vitro transcription
RiboMAX Large Scale RNA Production System (Promega,
Madison, WI, USA) was used for in vitro transcription of pCI/tau39
or pCI/tau40. pCI/tau39 or pCI/tau40 was linearized by digestion
with BamHI and SalI, and the DNA template was puriﬁed by phenol
extraction and ethanol precipitation. The linearized DNA was
added into reaction mixture according to the manufacturer’s pro-
tocol. The reaction mixture was incubated at 37 C for 2 h, and then
the DNA template was removed by 1 lg/ll RQ1 RNase-free DNase
(Promega). The in vitro transcripted mRNA was analyzed by 1.5%
agarose gel.
2.5. Electrophoretic mobility shift assay (EMSA)
RNA primer of tau exon 10 containing SC35-like enhancer
(50GUGCAGAUAAUUAAUAAGAAGCUGGAUCUU30) was labeled
with [c-32P]ATP (4500 Ci/mmol) using T4 polynucleotide kinase
(New England Biolabs) and subsequently puriﬁed with MicroSpin
G-25 column (Amersham Biosciences). To perform the EMSA assay,
the recombinant protein in the buffer (50 mM Tris–HCl, pH 7.5,
50 mMNaCl, 1 mM EDTA and 1 mM dithiothreitol) was mixed with
32P-labeled tau RNA primer in a total volume of 10 ll. The reaction
mixture was incubated at 37 C for 40 min and analyzed with a 6%
non-denaturing polyacrylamide gel, which was pre-run at 100 V
for 10 min. Electrophoresis was carried out in TBE buffer (89 mM
Tris borate, 2 mM EDTA) at 100 V for 60 min. The gel was dried
and autoradiographed with a PhosphorImager (BAS-1500, Fuji-
ﬁlm). The RNA substrates used in all experiments were at 2.4 nM,
and the amounts of proteins were indicated in the ﬁgure legends.
2.6. Preparation of nuclear and cytoplasmic extracts
Nuclear and cytoplasmic extracts were prepared with NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Thermo scientiﬁc,
Rockford, IL) according to manufacture’s protocol. Brieﬂy, cells
were suspended in ice-cold CER I and incubated on ice for10 min, and then ice-cold CER II was added and incubated on ice
for another 1 min. After centrifuging for 5 min at 16 000g, the
supernatant was collected as cytoplasmic extract. The pellet con-
taining nuclei was suspended in ice cold NER and placed on ice.
After vortexing for 15 s every 10 min for a total of 40 min, the
16 000g supernatant was collected as nuclear extract.
2.7. RNA immunoprecipitation (RNA-IP)
The RNA-IP experiment was performed as described [27–29].
Brieﬂy, HEK-293T cells co-transfected with pCEP4/SC35 and
pEGFP/tau39 or pEGFP/tau40 were incubated in PBS containing
1% formaldehyde at room temperature for 10 min, and then glycine
was added to 125 mM to block free aldehyde groups. The cells
were lyzed with lysis buffer (16.7 mM Tris, pH 8.1, 0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 167 mMNaCl, protease inhibitors
cocktail, 50 U/ml SUPERasein), and sonicated three times for 10 s
each (resulting in an average fragment size of 0.5–1 kb). The super-
natant was incubated with anti-HA to immunoprecipitate SC35.
After successive washing, the precipitates were eluted with 1%
SDS, 0.1 M NaHCO3, 50 U/ml SUPERasein, and decrosslinked by
adding NaCl to 200 mM and incubating at 65 C for about 2 h.
The RNA was puriﬁed from the immunoprecipitates with RNeasy
mini kit (Qiagen GmbH, Germany) after protein and DNA were di-
gested by Proteinase K at 42 C for 45 min and by RQ1 Rnase-free
Dnase (Promega) at 37 C for 15 min, respectively. After reverse-
transcription, PCR reactions were carried out with Prime-STARTM
HS DNA Polymerase (Takara Bio Inc., Otsu, Shiga, Japan) with prim-
ers Forward: 50ccgcctgcagacagcccccgtgcccatgccagac30, Reverse:
50cttccacctggccacctcctggtttatgatggatg30. An initial denature for
5 min 98 C was followed by 30 cycles with 98 C for 10 s – 55 C
for 15 s – 72 C for 30 s and a ﬁnal extension for 10 min at 72 C.
PCR products were separated on a 1.5% agarose gel and visualized
by ethidium bromide staining.3. Results
3.1. SC35 increases the expression of tau
We recently demonstrated that the splicing factor SC35 acts on
a SC35-like enhancer at 50 exon 10 and promotes tau exon 10 inclu-
sion ([7] and unpublished data). As expected, overexpression of
SC35 in HEK-293T cells time-dependently enhanced the inclusion
of tau exon 10 in mini-tau gene, pCI/SI9-SI10, which was consisted
of exons 9, 10, and 11 and part of introns 9 and 10, (Fig. 1A and B).
We also observed unexpectedly a time-dependent increase in the
total tau mRNAwith SC35 over-expression (Fig. 1A and C), suggest-
ing that SC35 may regulate tau expression besides tau splicing. To
investigate this possibility, we co-transfected pEGFP/tau40 to-
gether with various amounts of pCEP4/SC35 into HEK-293T cells
and then measured the levels of tau and SC35 after 48 h transfec-
tion. We observed a dose-dependent expression of SC35, as deter-
mined by antibody against HA that was tagged to SC35 (Fig. 1D).
The expression level of tau40 also increased along with the
increasing dose of pCEP4/SC35 (Fig. 1D and E), indicating that
SC35 enhanced the expression of tau40 in HEK-293T cells.
3.2. SC35 promotes tau expression in a manner dependent on exon 10
To determine whether SC35 regulates the expression of other
tau isoforms (Fig. 2A), we co-transfected into HEK-293T cells with
pCEP4/SC35 and pEGFP/tau40, pEGFP/tau39, pEGFP/tau23, pEGFP/
tau24, pEGFP/tau37 or pEGFP/tau46, respectively. After 48 h trans-
fection, both the protein and the mRNA levels of each tau isoform
were measured by using Western blots and RT-PCR, respectively.
Fig. 1. Overexpression of SC35 promotes tau exon 10 inclusion and expression of tau40. (A) Tau mini-gene pCI/SI9-SI10 was co-transfected with pCEP4/SC35 into HEK-293T
cells for various times, and then the splicing products of tau exon 10 were measured by RT-PCR. The tau exon 10 inclusion/exclusion ratio (B) and the total PCR products
(mRNA) (C) are plotted against the transfection time. (D and E) pEGFP/tau40 was co-transfected with different amount of pCEP4/SC35 into HEK-293FT cells. After a 48-h
transfection, the level of tau40, SC35, and actin were determined by Western blots developed with speciﬁc anti-tau (R134d), anti-HA, and anti-actin antibodies, respectively.
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of tau isoforms containing the second microtubule-binding repeat
encoded by exon 10 (i.e., 4R-taus, including tau24, tau46, and
tau40) were increased signiﬁcantly (Fig. 2). To the contrary, the
expression of 3R-taus, including tau23, tau37, and tau39, was
either decreased (tau23, tau39) or unchanged (tau37). These data
suggest that SC35-induced increase in tau level probably resulted
from an increase in the expression of tau and that tau exon 10
was required for the SC35’s activity to promote tau expression.
3.3. SC35 stabilizes tau mRNA
To determine the mechanism by which SC35 increased 4R-tau
expression, we determined whether SC35 promotes tau transcrip-
tion. To this aim, we immuno-puriﬁed SC35 protein by using Pro-
tein G beads cross-linked with anti-HA antibody and then added
the puriﬁed SC35 to an in vitro transcription system. We found that
addition of SC35 did not alter the amount of mRNA of tau39 or
tau40 synthesized in vitro (Fig. 3A). These results suggest that
SC35 is unlikely to regulate tau transcription.
For protein expression, mRNA needs to be transported to the
cytoplasm from nucleus before protein translation. To investigate
whether SC35 affects tau mRNA transport, we co-transfected
HEK-293FT cells with pCEP4/SC35 and different tau isoforms, we
fractionated the transfected cells into nuclear and cytoplasmic
fractions, extracted RNA from both fractions, and then measured
the mRNA level of tau by RT-PCR. We found that SC35 did not
change the nuclear to cytoplasmic ratio of tau mRNA (Fig. 3B), sug-
gesting that SC35 does not affect tau mRNA transport.
To identify if SC35 affects the stability of 4R-tau mRNA, we
overexpressed SC35 with tau40 in HEK-293T cells and measured
the turn-over of tau40 mRNA after new RNA synthesis was sup-
pressed by actinomycin D, a transcription inhibitor. We observeda rapid tau decrease in tau40 mRNA in the presence of actinomycin
D, but the tau40 mRNA reduction was prevented when SC35 was
co-expressed (Fig. 3C). These results suggest that co-expression
of SC35 inhibits the degradation of tau40 mRNA (Fig. 3C). Thus, it
appears that SC35 increases 4R-tau expression via stabilization of
the mRNA.
3.4. SC35 binds to tau mRNA through exon 10
To understand why SC35 promoted the expression of 4R-tau but
not of 3R-tau, we investigated the binding between SC35 and tau
mRNA. To this aim, we immunoprecipitated SC35 48 h after HEK-
293T cells were co-transfected with pCEP4/HA-SC35 and pEGFP/
tau39 or pEGFP/tau40. Tau mRNA co-immunoprecipitated with
SC35 was then ampliﬁed by RT-PCR and examined by agarose gel
electrophoresis. We found only tau40, but not tau39, in the SC35
immunoprecipitates (Fig. 4A), suggesting that SC35 binds to
tau40 mRNA, but not tau39 mRNA.
To localize the binding site of tau mRNA to SC35, we labeled a
30-nt RNA oligomer that was SC35-like enhancer of tau exon 10
with 32P and incubated it with various amounts of puriﬁed SC35.
Electrophoresis of the incubated mixtures in native gels revealed
a radioactive band that was consistent to the size of the SC35–
RNA complex (Fig. 4B). The band radioactivity correlated to the
amounts of SC35 added into the incubation mixtures. These results
suggest that SC35 binds to tau mRNA through exon 10.
4. Discussion
The SR proteins play important roles in both constitutive splic-
ing and alternative splicing [7,30,31]. As an important member of
SR proteins, SC35 regulates the alternative splicing of tau. Overex-
pression of SC35 promotes tau exon 10 inclusion [7]. We recently
Fig. 2. Overexpression of SC35 differentially regulates the expressions of mRNA and protein of six tau isoforms. (A) Diagram of six human tau isoforms. (B) pEGFP/tau40 (left
panel) or pEGFP/tau39 (right panel) was co-transfected with pCEP4/SC35 or empty vector (Con) into HEK-293T cells. The total RNA was subjected to RT-PCR for measurement
of mRNA level of tau39 and tau40 (upper panels). The protein levels of tau39 and tau40 were examined by Western blots developed with anti-tau (R134d) (lower panels). (C)
The mRNA levels of six isoforms of tau were quantitated by densitometry and normalized by mRNA level of GAPDH. The data are presented as means ± S.D. ⁄P < 0.05 versus
control transfection. (D) The protein levels of six isoforms of tau were quantitated by densitometry and normalized by the level of actin. The data are presented as
means ± S.D. ⁄P < 0.05 versus control transfection.
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on the SC35-like enhancer of tau exon 10 (unpublished data). In
the present study, by using intronless tau constructs, we found that
SC35 enhanced 4R-tau but not 3R-tau expression at both the
mRNA and protein levels. We identiﬁed, for the ﬁrst time, that
SC35 stabilized mRNA and promoted 4R-tau expression by acting
on the exon 10 of tau mRNA. Our results suggest a broader role
for SC35 in the expression of tau in addition to its function in thealternative splicing of tau exon 10. Because only 4R-tau expression
was found to be up-regulated by SC35, our ﬁndings also provide a
novel molecular mechanism involved in the regulation of 3R-tau
and 4R-tau expression.
Increasing evidence suggests that the SR proteins not only reg-
ulate splicing of pre-mRNA, but also are involved in other events
from gene to protein cascade, including transcription, transporta-
tion, and translation. SC35 is reported to play an active role in
Fig. 3. SC35 has no detectable effect on transcription but regulates the processing of tau mRNA. (A) mRNAs of tau39 and tau40 were biosynthesized in vitro in the absence or
in the presence of puriﬁed SC35. The synthesized mRNA was then analyzed by gel electrophoresis. (B) HEK-293FT cells were co-transfected with pCEP4/SC35 and different
isoforms of tau. The total tau mRNA extracted from the nuclear and the cytoplasmic fractions was measured by RT-PCR, and the ratio of nuclear:cytoplasmic tau mRNA was
calculated and presented as an average from two separate experiments. (C) HEK-293T cells were treated with actinomycin D (2 lg/ll) for 0, 3, 6, and 10 h after transfection
with tau40 alone or together with SC35 for 48 h. RNAs were then extracted and tau40 mRNA was measured by RT-PCR and analyzed by agarose gel electrophoresis (upper
panel). The levels of tau40 mRNA are plotted after normalization to control GAPDH RNA on the basis of densitometry analysis (lower panel).
Fig. 4. SC35 binds to exon 10 of tau40 mRNA. (A) HEK-293T cells were harvested
48 h after co-transfection with pCEP4/HA-SC35 and either pEGFP/tau39 or pEGFP/
tau40, and SC35 from the cell lysates was immunoprecipitated by using anti-HA
antibody. Tau mRNA of the immunoprecipitates was ampliﬁed and detected by
agarose gel electrophoresis. (B) Various amounts of puriﬁed SC35 were incubated
with c 32P-labeled tau exon 10 oligomers for 40 min, followed by gel electropho-
resis and autoradiography.
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present study, we found that SC35 increased the level of 4R-tau
mRNA, but this increase was not resulted from increased transcrip-
tion as demonstrated by our in vitro transcription data. Further
studies indicated that SC35 increased the level of tau mRNA by
binding to exon 10 of tau mRNA and consequently stabilizing the
mRNA. Therefore, the ability of SC35 to stabilize tau mRNA was
dependent on the presence of exon 10. The expression of only
those isoforms that contained exon 10 (i.e., 4R-taus), but not the
isoforms without exon 10, was elevated by SC35 as a result of
the mRNA stabilization. Our observation is consistent with the fact
that there is a SC35-like enhancer at the 50 of tau exon 10 [32].However, overexpression of SC35 did not affect the level of tau37
at both mRNA and protein, suggesting tau37 mRNA might have a
weak SC35 acting site between exon 2 and exon 4, which need to
be identiﬁed.
It is known that some SR proteins, i.e., ASF and 9G8, shuttle be-
tween nucleus and cytoplasm and help mRNA transport from nu-
cleus to cytoplasm [33,34]. In the present study, we found that
overexpression of SC35 did not affect the distribution of tau mRNA
between the nucleus and the cytoplasm, suggesting a minimal role
of SC35 on the transportation of tau mRNA.
The activity of SC35 to regulate alternative splicing is tightly
regulated by its phosphorylation. GSK-3b and Dyrk1A phosphory-
late SC35 and modulate its function in the alternative splicing of
tau exon 10 ([31] and our unpublished data). Both kinases are
up-regulated in AD brain [35,36]. Whether SC35’s activity to
stabilize the 4R-tau mRNA is also regulated by its phosphorylation
catalyzed by GSK-3b and Dyrk1A remains to be elucidated. Under-
standing of the molecular mechanism by which up-regulation of
these kinases modulates the alternative splicing and the level of
tau in the brain will provide novel insight into the molecular
pathogenesis of AD and probably other related tauopathies.
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